X
Xenoport
A biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders
About Xenoport
Arbor Pharmaceuticals, based in Atlanta, Georgia, is a specialty pharmaceutical company focused on marketing prescription products across various therapeutic areas including cardiovascular, hospital, neuroscience, and pediatric markets. The company is led by a team of experienced pharmaceutical veterans, many of whom have backgrounds as healthcare practitioners, providing them with a deep understanding of the pharmaceutical development process and the value their products bring to patients' lives. Arbor Pharmaceuticals operates in the highly regulated pharmaceutical market, serving healthcare providers and patients who require specialized prescription medications. The business model revolves around the development, marketing, and sale of branded prescription products, with several products currently in late-stage development. Revenue is generated through the sale of these prescription medications to hospitals, clinics, and pharmacies. Arbor Pharmaceuticals aims to improve lives by advancing medicine, leveraging their expertise to bring innovative treatments to market.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 1999
- Headquarters
- Santa Clara, Cuba
- Employees
- 113
- Open positions
- None listed
- Dealroom signal
- 36.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | May 2016 | $467M | $467M | Undisclosed | — |
| LATE VCOther financing | Nov 2012 | $20M | $80M | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Xenoport is 0 monthly website visits. Xenoport's team declined 5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Series B and later1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Xenoport on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Xenoport’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.